2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117380
    SB 235375 224961-34-6 98%
    SB 235375 is a potent and selective antagonist of the human neurokinin-3 (hNK-3) receptor designed by optimizing the structure of 2-phenyl-4-quinolinecarboxylic acid amide. SB 235375 displays high affinity for the hNK-3 receptor, with significantly higher binding affinities than hNK-2 and hNK-1 receptors. In vitro studies demonstrated its ability to block NK-3 receptor-mediated contraction and calcium mobilization, while in vivo, SB 223412 demonstrated oral and intravenous activity against NK-3 receptor-driven responses in animal models.
    SB 235375
  • HY-117381
    γ-secretase-IN-2 564462-36-8 98%
    γ-secretase-IN-2 (Compound 34) is an inhibitor for γ-secretase, with an IC50 of 0.06 nM. γ-secretase-IN-2 can be used for the study of Alzheimer's disease.
    γ-secretase-IN-2
  • HY-117467
    BMT-108908 1801151-15-4 98%
    BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power.
    BMT-108908
  • HY-117471
    Antiarrhythmic agent-3 21236-52-2 98%
    Antiarrhythmic agent-3 is an antiarrhythmic drug with the activity of enhancing antiarrhythmic efficacy and improving inhibition index. The antiarrhythmic effect of antiarrhythmic agent-3 is related to its hydrophobicity (log P). The central nervous system toxicity of antiarrhythmic agent-3 is related to the combined effect of its hydrophobicity and acid constant (pKa).
    Antiarrhythmic agent-3
  • HY-117497
    Simetride 154-82-5 98%
    Simetride is an analgesic agent. Simeicui is used for pain relief.
    Simetride
  • HY-117507
    U92016A hydrochloride 149654-41-1 98%
    U92016A hydrochloride is a potent, metabolically stable, orally acitive 5-HT1A receptor agonist with an exceptionally high degree of intrinsic activity. U92016A hydrochloride binds with high affinity to human 5-HT1A receptors expressed in Chinese hamster ovary cells (Ki=0.2 nM).
    U92016A hydrochloride
  • HY-117526
    (-)-Mesembrine 24880-43-1 98%
    (-)-Mesembrine, a psychoactive alkaloid, is a partial racemate in S. strictum and S. tortuosum in smaller amounts.
    (-)-Mesembrine
  • HY-117533
    UNC0006 1354030-14-0 98%
    UNC0006 is a β-arrestin-biased dopamine D2 ligand. UNC0006 can be used in the study of antipsychotic.
    UNC0006
  • HY-117542
    D595 16740-29-7 98%
    D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers.
    D595
  • HY-117575
    WAY-100135 133025-23-7 98%
    WAY-100135 is a serotonergic compound belonging to the phenylpiperazine family, utilized in scientific research for its role as a strong antagonist of the 5-HT1A receptor and a partial agonist of the 5-HT1D receptor, with minimal activity at the 5-HT1B receptor.
    WAY-100135
  • HY-117578
    KB 5666 131916-69-3 98%
    KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia.
    KB 5666
  • HY-117606
    LY3027788 1377615-76-3 98%
    LY3027788, a diester analog of LY3020371 which is an mGlu2/3 receptor antagonist, is a potent and orally active prodrug of LY3020371. LY3027788 has antidepressant efficacy.
    LY3027788
  • HY-117609
    UE2343 1346013-80-6 98%
    UE2343 is an orally available, brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. UE2343 is being investigated for the treatment of Alzheimer's disease.
    UE2343
  • HY-117611
    GAT107 1476807-74-5 98%
    GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators).
    GAT107
  • HY-117637
    ALS-I-41 1369357-99-2 98%
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys.
    ALS-I-41
  • HY-117646
    FG-5893 150527-23-4 98%
    FG-5893 is a 5-HT1A receptor agonist and a 5-HT2 receptor antagonist. FG-5893 has anxiolytic effect.
    FG-5893
  • HY-117694
    MK-8825 1380887-60-4 98%
    MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC50 value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine.
    MK-8825
  • HY-117714
    AZD-3161 1369501-46-1 98%
    AZD-3161 is a potent and selective blocker of NaV1.7 channel, with a pIC50 of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain.
    AZD-3161
  • HY-117731
    UKH-1114 2113664-14-3 98%
    UKH-1114 is a potent σ2 receptor/Tmem97 agonist with a Ki value of 46 nM, showing antimechanical hypersensitivity effects. UKH-1114 alleviates mechanical hypersensitivity caused by nerve injury without any movement disorders in mice. UKH-1114 is promising for research of neuropathic pain.
    UKH-1114
  • HY-117739
    BRD1652 1597438-92-0 98%
    BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases.
    BRD1652
Cat. No. Product Name / Synonyms Application Reactivity